Clinical trial · Interventional
Study on the Prediction of Regional Lymph Node Metastasis in Colorectal Cancer by Spectral CT Combined With MSI
NCT07565831CI-TRIAL-00110233active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study on the prediction of regional lymph node metastasis in colorectal cancer by spectral CT combin
- description
- Prospectively collect medical images and clinical data related to colorectal cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accuratestaging of colorectal cancer. Patientsdiagnosed with colorectal cancer in Yunnan Provincial Cancer Hospital from August 2025 to December 2026 were consecutively included,and after scanning with Philips Quark CT, the TNM stage of colorectal cancer patients was assessed by two radiologists, and finally statistical analysis was performed
- interventionNames
- Diagnostic Test: Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes.
Primary outcomes (1)
- measure
- Pathological TNM staging
- timeFrame
- 1 day
- description
- Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Undergo contrast-enhanced Quark energy spectral CT examination of the lower abdomen/pelvis within 1 week before treatment;(2) MSI status confirmed;(3) Age \>18 years;(4) Patients with suspected colorectal cancer;(5) Patients who provided informed consent. Exclusion Criteria: * (1) Severe cardiac, pulmonary, or renal insufficiency;(2) Allergy to iodine-based contrast agents;(3) Inability to cooperate during the CT examination;(5) Poor image quality from Quark spectral CT scans;(6) Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.